Skip to main content


Fig. 1 | BMC Psychiatry

Fig. 1

From: N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial

Fig. 1

Trial flowchart. Eventually 200 patients will be required to finish the treatment study, being randomly divided into two groups including Trial arm 1 (antidepressant + NAC, n = 100) and Trial 2 (antidepressant + placebo, n = 100). For the fMRI scanning at baseline (week 0) and the 12th week, 50 patients will be included

Back to article page